-
公开(公告)号：EP3470535B1
公开(公告)日：2020-04-01
申请号：EP18190058.0
申请日：2004-06-17
发明人： BRYANT, John L. , PAIK, Soonmyung , BAKER, Joffre , SHAK, Steve
IPC分类号： C12Q1/6886
-
2.发明公开
公开(公告)号：EP1974058A2
公开(公告)日：2008-10-01
申请号：EP07717900.0
申请日：2007-01-11
发明人： COWENS, Wayne , BAKER, Joffre, B. , CLARK, Kim , HACKETT, James , WATSON, Drew , PAIK, Soonmyung
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G01N33/57419 , G01N33/57446
摘要： A method of predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection of said cancer is disclosed. A normalized expression level is determined of an RNA transcript of MYBL2, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject. The likelihood of a positive clinical outcome for said human subject is then predicted based on said normalized expression level, wherein normalized expression of an RNA transcript of MYBL2, or an expression product thereof, is positively correlated with an increased likelihood of a positive clinical outcome.
-
公开(公告)号：EP1644858B1
公开(公告)日：2017-12-06
申请号：EP04777383.3
申请日：2004-06-30
发明人： BAKER, Joffre , BRYANT, John, L. , PAIK, Soonmyung , SHAK, Steven
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57415 , G01N33/57484 , G01N33/57492 , G06F19/20 , G06F19/24
摘要： The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
-
公开(公告)号：EP1641810B1
公开(公告)日：2014-05-14
申请号：EP04809450.2
申请日：2004-06-17
发明人： BAKER, Joffre , BRYANT, John L. , PAIK, Soonmyung , SHAK, Steven
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
-
公开(公告)号：EP3470535A1
公开(公告)日：2019-04-17
申请号：EP18190058.0
申请日：2004-06-17
发明人： BRYANT, John L. , PAIK, Soonmyung , BAKER, Joffre , SHAK, Steve
IPC分类号： C12Q1/6886
摘要： Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
-
6.发明授权
公开(公告)号：EP1974058B1
公开(公告)日：2014-06-11
申请号：EP07717900.0
申请日：2007-01-11
发明人： COWENS, Wayne , BAKER, Joffre, B. , CLARK, Kim , HACKETT, James , WATSON, Drew , PAIK, Soonmyung
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G01N33/57419 , G01N33/57446
-
7.发明授权MOLECULAR INDICATORS OF BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE 有权分子指标用于乳腺癌预后和治疗反应预测到治疗
公开(公告)号：EP1815014B1
公开(公告)日：2012-03-21
申请号：EP05821698.7
申请日：2005-11-04
IPC分类号： C12Q1/68 , G01N33/574 , C12N15/10
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G06F19/18 , G06F19/20
摘要： The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measures as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotheraphy.
-
8.发明公开MOLECULAR INDICATORS OF BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE 有权分子指标用于乳腺癌预后和治疗反应预测到治疗
公开(公告)号：EP1815014A2
公开(公告)日：2007-08-08
申请号：EP05821698.7
申请日：2005-11-04
IPC分类号： C12Q1/68 , G01N33/574 , C12N15/10
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G06F19/18 , G06F19/20
摘要： The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measures as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotheraphy.
-
公开(公告)号：EP1836629B1
公开(公告)日：2020-03-04
申请号：EP05817266.9
申请日：2005-11-04
IPC分类号： G16B20/00 , C12Q1/6886 , G16B25/00
-
公开(公告)号：EP3330875A1
公开(公告)日：2018-06-06
申请号：EP17205130.2
申请日：2004-06-30
发明人： BAKER, Joffre , BRYANT, John, L. , PAIK, Soonmyung , SHAK, Steven
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57415 , G01N33/57484 , G01N33/57492 , G06F19/20 , G06F19/24
摘要： The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.025 秒)
